Cargando…

Apatinib in refractory radiation-induced brain edema: A case report

RATIONALE: Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has observed to be effective and safe in refractory radiation-induced brain edema, like Avastin did. Till now, there is no case report after apatinib came in the market. PATIENT CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wei Guo, Weng, Yi Ming, Dong, Yi, Li, Xiang Pan, Song, Qi-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704783/
https://www.ncbi.nlm.nih.gov/pubmed/29145238
http://dx.doi.org/10.1097/MD.0000000000007358
_version_ 1783281967800778752
author Hu, Wei Guo
Weng, Yi Ming
Dong, Yi
Li, Xiang Pan
Song, Qi-Bin
author_facet Hu, Wei Guo
Weng, Yi Ming
Dong, Yi
Li, Xiang Pan
Song, Qi-Bin
author_sort Hu, Wei Guo
collection PubMed
description RATIONALE: Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has observed to be effective and safe in refractory radiation-induced brain edema, like Avastin did. Till now, there is no case report after apatinib came in the market. PATIENT CONCERNS: Two patients who received brain radiotherapy developed clinical manifestations of brain edema, including dizziness, headache, limb activity disorder, and so on. DIAGNOSES: Two patients were both diagnosed as refractory radiation-induced brain edema. INTERVENTIONS: Two patients received apatinib (500 mg/day) for 2 and 4 weeks. OUTCOMES: Two patients got symptomatic improvements from apatinib in different degrees. Magnetic resonance imaging after apatinib treatments showed that compared with pre-treatment imaging, the perilesional edema reduced dramatically. However, the toxicity of apatinib was controllable and tolerable. LESSONS: Apatinib can obviously relieve the symptoms of refractory radiation-induced brain edema and improve the quality of life, which offers a new method for refractory radiation-induced brain edema in clinical practices. But that still warrants further investigation in the prospective study.
format Online
Article
Text
id pubmed-5704783
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-57047832017-12-07 Apatinib in refractory radiation-induced brain edema: A case report Hu, Wei Guo Weng, Yi Ming Dong, Yi Li, Xiang Pan Song, Qi-Bin Medicine (Baltimore) 6100 RATIONALE: Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has observed to be effective and safe in refractory radiation-induced brain edema, like Avastin did. Till now, there is no case report after apatinib came in the market. PATIENT CONCERNS: Two patients who received brain radiotherapy developed clinical manifestations of brain edema, including dizziness, headache, limb activity disorder, and so on. DIAGNOSES: Two patients were both diagnosed as refractory radiation-induced brain edema. INTERVENTIONS: Two patients received apatinib (500 mg/day) for 2 and 4 weeks. OUTCOMES: Two patients got symptomatic improvements from apatinib in different degrees. Magnetic resonance imaging after apatinib treatments showed that compared with pre-treatment imaging, the perilesional edema reduced dramatically. However, the toxicity of apatinib was controllable and tolerable. LESSONS: Apatinib can obviously relieve the symptoms of refractory radiation-induced brain edema and improve the quality of life, which offers a new method for refractory radiation-induced brain edema in clinical practices. But that still warrants further investigation in the prospective study. Wolters Kluwer Health 2017-11-17 /pmc/articles/PMC5704783/ /pubmed/29145238 http://dx.doi.org/10.1097/MD.0000000000007358 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 6100
Hu, Wei Guo
Weng, Yi Ming
Dong, Yi
Li, Xiang Pan
Song, Qi-Bin
Apatinib in refractory radiation-induced brain edema: A case report
title Apatinib in refractory radiation-induced brain edema: A case report
title_full Apatinib in refractory radiation-induced brain edema: A case report
title_fullStr Apatinib in refractory radiation-induced brain edema: A case report
title_full_unstemmed Apatinib in refractory radiation-induced brain edema: A case report
title_short Apatinib in refractory radiation-induced brain edema: A case report
title_sort apatinib in refractory radiation-induced brain edema: a case report
topic 6100
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704783/
https://www.ncbi.nlm.nih.gov/pubmed/29145238
http://dx.doi.org/10.1097/MD.0000000000007358
work_keys_str_mv AT huweiguo apatinibinrefractoryradiationinducedbrainedemaacasereport
AT wengyiming apatinibinrefractoryradiationinducedbrainedemaacasereport
AT dongyi apatinibinrefractoryradiationinducedbrainedemaacasereport
AT lixiangpan apatinibinrefractoryradiationinducedbrainedemaacasereport
AT songqibin apatinibinrefractoryradiationinducedbrainedemaacasereport